Frontlight ResearchEarly access
SuspendedPhase 1/2
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
Key facts
- Who runs it
- Sclnow Biotechnology Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- Phase
- Phase 1/2
- People taking part
- 40 people, planned
- Starts
- 31 Dec 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Allogeneic umbilical cord mesenchymal stem cells
- Decitabine
- Record updated
- 23 April 2026
- Why it stopped
- Others
Who can take part
- Age
- 60 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- MDS patients with international prostate symptom score is moderate or severe symptoms
Who cannot take part
- under other therapy that possibly influence MSC security or efficacy
- bad physical condition (Karmofsky < 60%)
- HIV or other serious disease infection
- Donor: HIV, active hepatitis B/C infection, Syphilitic antibody positive
- Donor/ participants: alcoholism, drug addicted, mental disease
- with other organ function abnormal: acute hepatitis B, ejection fraction < 40%, serum bilirubin > 3mg/dl, liver function tests abnormal, central nervous system disease, mental disease
- with serious renal function impaired
- without signing informed consent form
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.
The 2 groups in the trial
- Experimental groupTreatment being tested
Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.
Treatment: Allogeneic umbilical cord mesenchymal stem cells and Decitabine
- Control groupPlacebo, for comparison
Basic medication: Decitabine; placebo: saline.
Treatment: Decitabine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)
- Record updated
- 23 April 2026